Tisotumab vedotin-tftv

(Tivdak®)

Tisotumab vedotin-tftv

Drug updated on 12/15/2023

Dosage FormLyophilized powder (intravenous; 40 mg)
Drug ClassMultiple
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Tivdak (tisotumab vedotin-tftv) Prescribing Information.2023Seagen Inc., Bothell, WA

Randomized Controlled Trials


Sex Distribution:

F:100%
M:0%
55Subjects

Year:

2020

Source:Clinical Cancer Research